JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Real-world outcomes of Adjuvant De Gramont versus Xelox chemotherapy in reSected gasTric cancER: a propensity score-matched analysis (ASTER study)

  • 0Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Cancer Gene Therapy +

|

July 27, 2025

|

July 27, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Adjuvant chemotherapy (aCT) for gastric cancer (GC) and esophago-gastric junction cancer (EGJC) showed similar outcomes between De Gramont (DG) and XELOX/FOLFOX (OXA) regimens in a European real-world study. Further research is needed for optimal treatment selection.

Area Of Science

  • Oncology
  • Gastroenterology
  • Clinical Trials

Background

  • The role of adjuvant chemotherapy (aCT) in gastric and esophago-gastric junction cancer (GC/EGJC) is debated.
  • Real-world data on chemotherapy regimen efficacy in GC/EGJC is limited.

Purpose Of The Study

  • To compare clinical outcomes of De Gramont (DG) versus XELOX/FOLFOX (OXA) regimens for aCT in GC/EGJC.
  • To evaluate the efficacy and safety of these regimens in a European real-world setting.

Main Methods

  • Retrospective, bicentric study of 255 patients treated with aCT (2001-2018).
  • Propensity score-matched (PSM) analysis comparing DG and OXA regimens.
  • Primary endpoints: disease-free survival (DFS) and overall survival (OS).

Main Results

  • PSM analysis included 160 patients (80 per arm).
  • Median DFS and OS did not significantly differ between DG and OXA groups initially.
  • PSM-adjusted analysis revealed a trend towards longer DFS and significantly improved OS with DG.

Conclusions

  • DG and OXA regimens demonstrate comparable efficacy in adjuvant treatment of resected GC/EGJC in Europe.
  • Age, ECOG PS, resection margins, and stage are key prognostic factors.
  • Prospective studies are needed to optimize regimen selection and patient stratification.